New drug duo aims to stop aggressive cervical cancer from coming back
NCT ID NCT07368985
Summary
This study is testing if adding two drugs, pembrolizumab and lenvatinib, after standard chemoradiation and brachytherapy can better control high-risk, locally advanced cervical cancer and prevent it from returning. It will involve about 87 adults with specific high-risk forms of the disease. The main goal is to see if this combination improves the rate of patients living without their cancer getting worse two years after treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER BY FIGO STAGE 2018 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Erasmus MC
Rotterdam, South Holland, 3015 GD, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.